Helping The others Realize The Advantages Of Tyrosinase-IN-12
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To guage several intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Principal trial targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis pe